[{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Gregory George"}]

Find Immunology Drugs in Phase III Clinical Development in AUSTRALIA

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will be used in Mesoblast’s lead product candidate Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD).

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 29, 2024

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Gregory George

                          Deal Size : $50.0 million

                          Deal Type : Financing

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Ryoncil (remestemcel-L) is an investigational therapy comprising mesenchymal stromal cells, for the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 07, 2024

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Ryoncil (remestemcel-l) have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines.

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 23, 2024

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Prochymal (remestemcel-L) is an off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells, evaluated for pediatric patients with SR-aGVHD.

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 25, 2024

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The agreement aims to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 21, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : BMT CTN

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Ryoncil (remestemcel-l) have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved...

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 21, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The net proceedings will be used to fund the launch and commercialization of the company’s lead product, Prochymal (remestemcel-L), in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 25, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : $40.0 million

                          Deal Type : Private Placement

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 08, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Remestemcel-L is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SRaGVHD by down-regulating pro-inflammatory cytokines, increasing production of antiinflammatory cytokines.

                          Product Name : Ryoncil

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Remestemcel-L

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank